Overview

VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)

Status:
Recruiting

Trial end date:
2021-11-30

Target enrollment:

Participant gender:

Summary

Open-labeled, multicenter phase II study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation in patients with stage III/IV extranodal NK/T-cell Lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Asparaginase
BB 1101
Busulfan
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Etoposide
Etoposide phosphate
Ifosfamide
Isophosphamide mustard
Melphalan